While combining PD-1 inhibitors with anti-angiogenic agents is a promising strategy, real-world evidence for chemo-free combinations in this specific population remains scarce.<h4>Methods</h4>This multicenter, retrospective case series evaluated 27 patients with advanced <i>KRAS</i>-mutant NSCLC who received sintilimab (200 mg IV, q3w) plus anlotinib (8-12 mg PO, d1-14, q3w) after ≥1 prior line of therapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.